Table 1.
Relationships between immunohistochemical expression of COX‐2 and 15‐PGDH and clinicopathological parameters
| Clinicopathological parameters | Total cases (n = 71) | Expression of 15‐PGDH | P‐values | Expression of COX‐2 | P‐values | ||
|---|---|---|---|---|---|---|---|
| Negative (n = 35) | Positive (n = 36) | Negative (n = 23) | Positive (n = 48) | ||||
| n (%) | n (%) | n (%) | n (%) | ||||
| Age | |||||||
| < 60 years | 12 | 7 (58.3) | 5 (41.7) | 0.711 | 3 (25.0) | 9 (75.0) | 0.739 |
| ≧60 years | 59 | 28 (47.5) | 31 (52.5) | 20 (33.9) | 39 (66.1) | ||
| Gender | |||||||
| Male | 49 | 24 (49.0) | 25 (51.0) | 0.937 | 17 (34.7) | 32 (65.3) | 0.537 |
| Female | 22 | 11 (50.0) | 11 (50.0) | 6 (27.3) | 16 (72.7) | ||
| Differentiation | |||||||
| Tubular | 39 | 14 (35.9) | 25 (64.1) | 0.013 | 9 (23.1) | 30 (76.9) | 0.204 |
| Poorly | 32 | 21 (65.6) | 11 (34.4) | 14 (43.8) | 18 (56.3) | ||
| Depth of invasion | |||||||
| mp | 13 | 6 (46.2) | 7 (53.8) | 0.269 | 6 (46.2) | 7 (53.8) | 0.775 |
| ss | 16 | 4 (25.0) | 12 (75.0) | 5 (31.3) | 11 (68.8) | ||
| se | 41 | 24 (58.5) | 17 (41.5) | 11 (26.8) | 30 (73.2) | ||
| si | 1 | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | ||
| Lymph node metastasis | |||||||
| Negative | 69 | 34 (49.3) | 35 (50.7) | 0.984 | 22 (31.9) | 47 (68.1) | 0.546 |
| Positive | 2 | 1 (50.0) | 1 (50.0) | 1 (50.0) | 1 (50.0) | ||
| Disease stage | |||||||
| I | 16 | 3 (18.8) | 13 (81.3) | 0.025 | 6 (37.5) | 10 (62.5) | 0.79 |
| II | 15 | 7 (46.7) | 8 (53.3) | 4 (26.7) | 11 (73.3) | ||
| III | 19 | 13 (68.4) | 6 (31.6) | 5 (26.3) | 14 (73.7) | ||
| IV | 21 | 12 (57.1) | 9 (42.9) | 8 (38.1) | 13 (61.9) | ||
15‐PGDH, 15‐hydroxyprostaglandin dehydrogenase; COX‐2, cyclooxygenase‐2; poorly, poorly differentiated adenocarcinoma; tubular, tubular adenocarcinoma.